Impact of the COVID-19 Outbreak on the management of patients with gynecological cancers

The exceptional health situation related to the SARS-Cov2 coronavirus pandemic (COVID-19) required a deep and very quickly adaptation of management practices in gynecological cancer. The main objective is to estimate the proportion of patients with treatment modifications. This is a multicenter pros...

Full description

Saved in:
Bibliographic Details
Published in:Gynécologie, obstétrique, fertilité & sénologie obstétrique, fertilité & sénologie, 2020-11, Vol.48 (11), p.777-783
Main Authors: Lamblin, G, Golfier, F, Peron, J, Moret, S, Chene, G, Nohuz, E, Lebon, M, Dubernard, G, Cortet, M
Format: Article
Language:fre
Subjects:
Antineoplastic Agents
Betacoronavirus
Breast Neoplasms - epidemiology
Breast Neoplasms - therapy
Coronavirus Infections - epidemiology
COVID-19
Female
France - epidemiology
Genital Neoplasms, Female - epidemiology
Genital Neoplasms, Female - therapy
Gynecologic Surgical Procedures - statistics & numerical data
Humans
Middle Aged
Pandemics
Patient Compliance - statistics & numerical data
Pneumonia, Viral - epidemiology
Prospective Studies
Radiotherapy - statistics & numerical data
Remote Consultation - statistics & numerical data
SARS-CoV-2
Withholding Treatment - statistics & numerical data
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The exceptional health situation related to the SARS-Cov2 coronavirus pandemic (COVID-19) required a deep and very quickly adaptation of management practices in gynecological cancer. The main objective is to estimate the proportion of patients with treatment modifications. This is a multicenter prospective study conducted in 3 university gynecological cancer departments (HCLyon, France) during the period of confinement (March 16 to May 11, 2020). All patients with non-metastatic breast cancer or gynecological cancer were included. The planned treatment, postponement, delay and organizational modifications (RCP, teleconsultations) were studied. Two hundred and five consecutive patients were included, average age 60.5±1.0. 7 patients (3.4%) had SARS-Cov-2 infection, 2 patients died. One hundred and twenty-two patients (59.5%) had a treatment maintained, 72 patients (35.1%) postponed, 11 patients (5.4%) cancelled. Of the 115 (56.1%) planned surgeries, 40 (34.8%) postponed, 7 cancelled (6.1%). 9 patients (7.8%) had a surgical modification. Of the 59 (28.8%) radiotherapy treatments scheduled, 24 (40.7%) postponed and 2 (3.4%) cancelled. Of the 56 (27.3%) chemotherapy treatment planned, 8 (14.3%) postponed and 2 (3.6%) cancelled. One hundred and forty-five patients (70.7%) have been discussed in multidisciplinary meeting. One hundred and fifty-eight patients (77%) had a teleconsultation system. Our study assessed the impact of the COVID-19 pandemic on therapeutic management of patients with gynecological cancer during the period of confinement. This will probably improve our management of an eventual epidemic rebound or future health crisis.
ISSN:2468-7189
DOI:10.1016/j.gofs.2020.09.011